
    
      The drug being tested in this study is called TAK-954. This study will assess the mass
      balance, metabolic profiles and routes of elimination of single intravenous dose of
      [14C]-TAK-954, and will determine the major circulating and excreted metabolites and
      single-dose PK of total radioactivity, TAK-954, THRX513466, and THRX 913682 in healthy male
      participants.

      The study will enroll approximately 6 participants. All participants will receive a single
      dose of [14C]-TAK-954 0.5 mg on Day 1.

      This single-center trial will be conducted in Netherlands. The overall time to participate in
      this study is approximately 6 to 7 weeks. Participants will make a final visit to the clinic
      15 days after last dose of study drug for a follow-up assessment.
    
  